Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authors

A Egeberg, L Skov

Originalsprog	Engelsk
Tidsskrift	British Journal of Dermatology
Vol/bind	179
Udgave nummer	1
Sider (fra-til)	222-223
Antal sider	2
ISSN	0007-0963
DOI	https://doi.org/10.1111/bjd.16690
Status	Udgivet - jul. 2018

Adgang til dokumentet

@article{399718003ec943109dacb35a2cc7952a,

title = "Drug survival of secukinumab for moderate-to-severe plaque psoriasis: reply from authors",

keywords = "Antibodies, Monoclonal, Biological Factors, Biosimilar Pharmaceuticals, Humans, Psoriasis",

author = "A Egeberg and L Skov",

year = "2018",

month = jul,

doi = "10.1111/bjd.16690",

language = "English",

volume = "179",

pages = "222--223",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Drug survival of secukinumab for moderate-to-severe plaque psoriasis

T2 - reply from authors

AU - Egeberg, A

AU - Skov, L

PY - 2018/7

Y1 - 2018/7

KW - Antibodies, Monoclonal

KW - Biological Factors

KW - Biosimilar Pharmaceuticals

KW - Humans

KW - Psoriasis

U2 - 10.1111/bjd.16690

DO - 10.1111/bjd.16690

M3 - Comment/debate

C2 - 29736995

SN - 0007-0963

VL - 179

SP - 222

EP - 223

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 1

ER -